Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 17/20 | 0.74 |
| ▸ | HTR2A known ✓ | P28223 | 14/20 | 0.74 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.49 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.49 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 12/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adipic Acid SCHEMBL173678 | 0.94 | HTR2C (0.70) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Alpha-Ketoglutaric Acid SCHEMBL174469 | 0.94 | HTR2C (0.65) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Malonic Acid SCHEMBL174816 | 0.91 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Glycolic Acid SCHEMBL173573 | 0.91 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Glutamic Acid SCHEMBL174564 | 0.87 | HTR2C (0.59) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL164205 | 0.86 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Maleic Acid SCHEMBL174415 | 0.86 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Fumaric Acid SCHEMBL174417 | 0.86 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Fumaric Acid SCHEMBL175130 | 0.86 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Iodide SCHEMBL174548 | 0.85 | HTR2C (0.96) | HTR2CHTR2AHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |